Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Proxalutamide  COVID-19 treatment studies for Proxalutamide  C19 studies: Proxalutamide  Proxalutamide   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
 
    
  
Proxalutamide for COVID-19
4 studies from 38 scientists
1,953 patients in 2 countries
Statistically significant improvement for mortality, ventilation, hospitalization, recovery, and viral clearance.
4 studies from 2 independent teams in 2 countries show statistically significant improvements in isolation.
COVID-19 Proxalutamide studies. Jun 2023. c19early.org/x
0 0.5 1 1.5+ All studies 78% Mortality 78% Hospitalization 72% Viral clearance 74% RCTs 78% RCT mortality 78% Early 71% Late 78% Favorsproxalutamide Favorscontrol
Proxalutamide COVID-19 studies. Proxalutamide has been officially adopted in all or part of 3 countries. Submit updates/corrections.
Jun 9
Cadegiani, F. (News) Frontiers Fraudulent Retraction
Details on the censorship of [McCoy].
Apr 8
Ma et al., AACR Annual Meeting 2022 (In Vitro) Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients
Review of the mechanisms of action of proxalutamide for COVID-19, and In Vitro results showing that proxalutamide inhibited SARS-CoV-2 wild type, alpha and delta variants, with IC50 of 69, 48 and 39nM. Only the abstract is currently avail..
Apr 5
Kintor News Release (News) Kintor Pharma's Proxalutamide Demonstrated Reduction in Hospitalization/Mortality for Patients with Mild to Moderate COVID-19 in Phase III MRCT Study
50% lower hospitalization [p=0.38] and 74% improved viral clearance [p=0.0001]. RCT 733 outpatients, 99% in the USA, showing lower hospitalization/death, and significantly reduced viral load with proxalutamide treatment. The viral clearance result is from [Ma].
Dec 27
2021
Kintor, News Releease (News) Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19
News release reporting on interim analysis of NCT04870606, showing that statistical criteria were not met, there was a very low event rate, and that Kintor plans to amend the protocol and continue to enroll higher risk patients.
Dec 25
2021
Cadegiani et al., Cureus, doi:10.7759/cureus.20691 Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial
78% lower mortality [p<0.0001], 45% improved recovery [p<0.0001], and 33% shorter hospitalization [p=0.0001]. RCT 778 hospitalized patients in Brazil, 423 treated with proxalutamide, showing significantly lower mortality and improved recovery with treatment. NCT04728802 and NCT05126628. Authors note that cases in this trial were predominantly the..
Dec 17
2021
Kintor, News Comments (News) 开拓药业普克鲁胺治疗新冠预计本月发布临床数据
News report noting that real-world results for proxalutamide in Paraguay show significantly lower mortality and are consistent with the results of previous studies in Brazil.
Jul 25
2021
Cadegiani et al., medRxiv, doi:10.1101/2021.07.24.21261047 (Preprint) Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide (The EAT-Proxa Biochemical AndroCoV-Trial)
Analysis of data from two proxalutamide early treatment RCTs with 445 patients showing substantial improvements in immunologic, inflammatory, thrombotic, and oxygen markers, which may support the observed reduction in hospitalization.
Jul 16
2021
Kintor Pharmaceutical News Release (News) Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay
News release announcing that proxalutamide has been granted an emergency use authorization for COVID-19 in Paraguay.
Jul 10
2021
Cadegiani et al., medRxiv, doi:10.1101/2021.07.06.21260086 (Preprint) Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial
90% lower ventilation [p=0.07] and 86% lower hospitalization [p=0.0008]. RCT 177 women in Brazil, 75 treated with proxalutamide, showing significantly lower hospitalization with treatment.
Jul 2
2021
Zimerman et al., medRxiv, doi:10.1101/2021.06.28.21259661 (Preprint) Proxalutamide (GT0918) Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration - an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial
Analysis of treatment duration in the Proxa-Rescue AndroCoV trial showing significantly higher mortality among patients that interrupted treatment with proxalutamide. NCT04728802.
Jul 1
2021
Medeiros et al., ResearchGate (Preprint) Proxalutamide (GT0918) Improves Lung Injury in Hospitalized COVID-19 Patients -an Analysis of the Radiological Findings of the Proxa-Rescue AndroCoV Trial
Analysis of radiological findings from the Proxa-Rescue AndroCoV trial showing that proxalutamide significantly improves lung opacities compared to placebo. NCT04728802.
Feb 22
2021
Cadegiani et al., Cureus, doi:10.7759/cureus.13492 Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
92% improved viral clearance [p<0.0001] and 77% improved recovery [p<0.0001]. RCT 234 mild-moderate COVID-19 patients with 171 treated with proxalutamide, showing significantly faster viral clearance and recovery. Third party analysis suggests potential randomization failure: [steamtraen.blogspot.com].
Dec 30
2020
McCoy et al., Frontiers in Medicine, doi:10.3389/fmed.2021.668698 (date from earlier preprint) Proxalutamide (GT0918) Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
97% lower ventilation [p<0.0001] and 91% lower hospitalization [p<0.0001]. RCT 268 male patients in Brazil, 134 treated with proxalutamide, showing significantly lower hospitalization and mechanical ventilation. NCT04446429. This paper was censored without details or author response, and the editors have ignored..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit